Risks
3 risks
Risk Intelligence
USFDA delays at Monroe and Goa facilities
View Risks →
Glenmark Pharmaceuticals Limited — Q1 FY25
Glenmark's Q1 FY25 consolidated revenue grew 6.9% YoY to INR 32,442 million, driven by strong India (11.9% YoY) and Europe (21.4% YoY) performance, while US remained soft.
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Glenmark's Q1 FY25 consolidated revenue grew 6.9% YoY to INR 32,442 million, driven by strong India (11.9% YoY) and Europe (21.4% YoY) performance, while US remained soft. EBITDA margin adjusted for forex was 18.8%, with full-year guidance of ~19%. Management expects US recovery in H2, driven by respiratory product approvals and Monroe facility resolution. RYALTRIS sales are on track for $80 million in FY25. Key risks include USFDA delays at Monroe and Goa facilities, and potential market share erosion in GLP-1 as semaglutide goes off-patent in 2026. IGI's clinical asset 2001 is progressing, with partnership expected in FY26.
ग्लेनमार्क की पहली तिमाही (अप्रैल-जून 2024) में कुल कमाई पिछले साल की तुलना में 6.9% बढ़कर 32,442 करोड़ रुपये हो गई। इसकी वजह भारत (11.9% बढ़ोतरी) और यूरोप (21.4% बढ़ोतरी) में अच्छी बिक्री रही, जबकि अमेरिका में कारोबार कमजोर रहा। कंपनी का मुनाफा (EBITDA) करीब 18.8% रहा और पूरे साल 19% मुनाफा रहने का अनुमान है। प्रबंधन को उम्मीद है कि साल की दूसरी छमाही में अमेरिका में सांस की दवाओं की मंजूरी और मुनरो फैक्ट्री की समस्या सुलझने से कारोबार सुधरेगा। RYALTRIS दवा की बिक्री इस साल 80 करोड़ डॉलर तक पहुंचने की उम्मीद है। जोखिमों में अमेरिकी नियामक (USFDA) की देरी और 2026 में सेमाग्लूटाइड दवा के पेटेंट खत्म होने से GLP-1 बाजार में हिस्सेदारी कम होना शामिल है। IGI की नई दवा 2001 पर काम चल रहा है और अगले साल तक साझेदारी की उम्मीद है।
Risks3 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
India Formulation Revenue Growth
11.9%
+11.9% YoY
India formulation business grew 11.9% YoY to INR 11,962 million, outperforming IPM growth of 8.7%.
Europe Revenue Growth
21.4%
+21.4% YoY
Europe operations grew 21.4% YoY to INR 6,957 million, driven by strong performance in CEE and branded respiratory.
RYALTRIS Market Coverage
90+ countries
N/A
Marketing applications for RYALTRIS submitted in over 90 countries; commercialized in 40 markets.
US Revenue Contribution
24.1%
-24.1% of total
US contributed 24.1% of consolidated revenue, down from historical levels, as Europe grows.
What Changed vs Last Quarter
NEW
Full-year EBITDA margin guidance of ~19%
Management guided to approximately 19% EBITDA margin for FY25, supported by India growth, RYALTRIS ramp-up, and lower R&D spend.
NEW
RYALTRIS sales target of $80 million in FY25
Management reiterated the target of $80 million in RYALTRIS sales for the full year, with new market launches expected in FY26.
NEW
US recovery expected in H2 FY25
Management expects US business to recover in the second half of FY25, driven by respiratory product approvals and Monroe facility restart.
NEW
IGI partnership expected in FY26
Management plans to partner IGI's clinical asset 2001 in FY26 after presenting data at ASH in December 2024.
DROPPED
FY25 consolidated revenue target INR 135,000-140,000 million
Management guided FY25 revenue between INR 135-140 billion, implying ~14-18% growth over FY24.
DROPPED
FY25 EBITDA margin target close to 19%
EBITDA margin expected to be near 19% for full year FY25, supported by mix improvement and cost control.
DROPPED
FY25 R&D investment 7%-7.25% of revenue
R&D spend guided at 7-7.25% of total revenue, with generic R&D increasing and IGI spend declining.
DROPPED
FY25 consolidated capital investment INR 7,000 million
CapEx of INR 700 crore planned for additional lines, Rialtris capacity, and in-licensing opportunities.
NEW RISK
USFDA delays at Monroe and Goa facilities
Monroe facility has an FDA meeting in September 2024, but no restart timeline; Goa remediation completed but inspection pending. Delays could impact US launches.
NEW RISK
GLP-1 market shift post-2026
Semaglutide patent expiry in 2026 may shift patients from liraglutide to newer GLP-1s, potentially limiting liraglutide's revenue potential.
NEW RISK
Working capital increase
CFO guided working capital days to increase to ~75 days from current 62 days, driven by business growth and receivables, which could pressure cash flows.
RISK GONE
Monroe facility FDA reinspection delay
Remediation completed but FDA reinspection pending; delay could impact injectable commercialization timeline.
RISK GONE
Elevated legal settlement cash outflows
Cash payout of ~INR 300 crore in FY25 for DOJ and Zetia settlements, impacting free cash flow.
RISK GONE
North America revenue decline and lack of launches
North America revenue fell 12.4% YoY; recovery depends on generic Flovent approval and scale-up of recent launches.
RISK GONE
IGI R&D spend remains high at $50 million
Despite earlier guidance to reduce Ichnos spend, FY25 IGI cash R&D is $50 million, pressuring profitability.
🤫 Topics management stopped discussing
Mentioned in Q2 FY24, Q4 FY24
EBITDA margin expected to be near 19% for full year FY25, supported by mix improvement and cost control.
Mentioned in Q1 FY24, Q2 FY24
Europe business expected to grow at a minimum of 15-20% going forward, driven by respiratory portfolio and Ryaltris.
Mentioned in Q1 FY24, Q2 FY24
India business growth was impacted by slowdown in respiratory and dermatology; while October showed recovery, sustainability is uncertain.
Mentioned in Q2 FY24, Q4 FY24
Remediation completed but FDA reinspection pending; delay could impact injectable commercialization timeline.
Fast read
Guidance and risk preview
Management guided to approximately 19% EBITDA margin for FY25, supported by India growth, RYALTRIS ramp-up, and lower R&D spend.
Monroe facility has an FDA meeting in September 2024, but no restart timeline; Goa remediation completed but inspection pending.
View Risks →